Nov 25, 2025
Newsroom
PharmaEssentia Announces Publication of Phase 3 SURPASS-ET Results in The Lancet Haematology
Learn MoreNov 11, 2025
Newsroom
PharmaEssentia USA Announces Appointment of Dr. Barry Flannelly as Independent Director
Learn MoreOct 6, 2025
Newsroom
Material Information - Hong Kong Department of Health has Approved the New Drug Registration of BESREMi (Ropeginterferon alfa-2b) for PV
Learn MoreSep 22, 2025
Newsroom
Material Information - Announcement of the U.S. FDA’s Positive Preliminary Comments on the Filing for Expansion of Indication of BESREMi for Essential Thrombocythemia (ET)
Learn MoreSep 18, 2025
Newsroom
Material Information - Announcement on Behalf of PharmaEssentia Japan KK: Filing for an Additional Indication of BESREMi (Ropeginterferon alfa-2b) for ET in Japan
Learn MoreSep 11, 2025
Newsroom
Material Information - The Health Canada has Accepted the New Drug Submission of Ropeginterferon alfa-2b for PV
Learn MoreSep 5, 2025
Newsroom
Material Information - PharmaEssentia Files for an Additional Indication of Besremi (Ropeginterferon alfa-2b) for the Treatment of Essential Thrombocythemia (ET) with TFDA
Learn MoreAug 19, 2025
Newsroom
PharmaEssentia to Participate at Morgan Stanley 23rd Annual Global Healthcare Conference
Learn More